The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
about
Targeting the insulin growth factor receptor 1Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endotheliumContinuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexGPCRs and cancerRelationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.G Protein-Coupled Receptor 87: a Promising Opportunity for Cancer Drug Discovery.Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.Somatostatin and cancer: applying endocrinology to oncology.Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and TherapeuticsAssociation between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesisClinical implications of neuroendocrine differentiation in prostate cancer.Somatostatin receptor scintigraphy in thoracic diseases.Illuminating somatostatin analog action at neuroendocrine tumor receptorsPeptide receptor therapies in neuroendocrine tumors.Pegvisomant: current and potential novel therapeutic applications.Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.Long-term survival in small cell lung cancer: a case report and review of the literature.Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.Inhibition of endothelial proliferation by the somatostatin analogue SOM230.Peptides and Drug Delivery.Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.Integrated analysis of tumor differentiation genes in pancreatic adenocarcinoma.Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)
P2860
Q24633750-DA8405C0-51B3-49F5-AB5E-995D38705A1DQ30486819-5CB47C95-9D85-4959-9D8E-E9F91544B9B2Q33514751-B84A0BF4-EC9A-476A-9971-5EC1462FC11EQ33718131-25072262-08D3-4931-A413-BFA79D780E48Q33828719-56F8F1C8-3553-4088-8D00-D2CCEFBEEDB5Q33867261-0FE61A33-553D-47E6-B8E5-911620A12721Q34034138-CF14B192-9337-44D6-B8C9-9321BB408FF4Q34091373-849A2C85-811F-493D-91E1-3E9E6CF7F2C3Q34181921-C04AB948-E49D-4DA0-A32D-1E0055686332Q34586300-A60D1CE7-0B96-42FD-B21F-F88D1543607AQ35057473-343CD5D8-8B51-4A9C-9663-E4A32956D9C1Q35103474-F1134FC4-FD9F-43DC-B3E5-0F4B9AEDC06BQ35148094-B6397618-0F88-4C01-8188-09A0F6BB2F85Q36008285-E22E6243-E636-40E8-82D4-94C2857550D1Q36474555-C17FC09F-1590-4C6E-BFFF-65B1AD2BBDA3Q36639877-F3604FB7-438C-4079-BE47-80C384D7B034Q37030460-3737DFB4-9D2B-4887-B071-A21EDFF235A4Q37443562-D9679145-243E-4181-B83E-778F3A39D5DAQ37563878-26048B22-9985-46D2-BA26-61C0D166D7AAQ37633543-B93B2145-C206-4898-9005-484B6B915DB2Q37696327-AF7350CD-3DB0-41AA-8476-5717CDA2C29BQ38175857-3FBBD5A5-5467-492A-BC23-068ECC0B9856Q38206270-E9172948-8F5E-4B15-B8E1-20BC4A770435Q38880901-FD08E114-D811-4EEC-AD67-C31E66BC86ABQ39274492-C35420C0-4DBE-42AC-BE9F-4798CF00AB54Q39741277-243F7232-C029-408D-80F2-954856CD5B9BQ45097765-E61789FF-AE7B-402D-8A9B-72CADAED86BAQ47590591-EDB2AA12-78A8-4FDC-AC64-00C9CED9ECFBQ49168467-77915A7F-1339-4F0E-B6C9-0A371CFFA044Q52560203-504F4ABE-8523-461C-8A22-26F716881BD2Q52723252-BBF36324-B4FB-4FB0-BD7D-654E91312550Q57142659-E964AFEA-5A74-42D6-A1E2-F976F15797F1
P2860
The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The clinical role of somatosta ...... gents: much ado about nothing?
@ast
The clinical role of somatosta ...... gents: much ado about nothing?
@en
The clinical role of somatosta ...... gents: much ado about nothing?
@nl
type
label
The clinical role of somatosta ...... gents: much ado about nothing?
@ast
The clinical role of somatosta ...... gents: much ado about nothing?
@en
The clinical role of somatosta ...... gents: much ado about nothing?
@nl
prefLabel
The clinical role of somatosta ...... gents: much ado about nothing?
@ast
The clinical role of somatosta ...... gents: much ado about nothing?
@en
The clinical role of somatosta ...... gents: much ado about nothing?
@nl
P2093
P356
P1433
P1476
The clinical role of somatosta ...... gents: much ado about nothing?
@en
P2093
P304
P356
10.1093/ANNONC/MDF142
P577
2002-05-01T00:00:00Z